Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2017—PerkinElmer has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd. Tulip, based in Goa, India, is a large domestic provider of in vitro diagnostic reagents, kits, and instruments to diagnostic labs and government and private health care facilities.
April 2017—Aushon BioSystems announced U.S. Patent No. 9,527,085, titled “Apparatus and method for dispensing fluid, semi-solid and solid samples,” was issued by the U.S. Patent and Trademark Office for microarray printing of complex biological and chemical fluids.
April 2017—Sarah Cannon, the cancer institute of Hospital Corporation of America, announced that Genospace LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
April 2017—Singulex has entered into a strategic collaboration with Qiagen to develop companion diagnostics. Through the collaboration, Qiagen will have access to Singulex’s Single Molecule Counting (SMC) immunodiagnostic platform, adding immunoassay capabilities to Qiagen’s existing molecular testing services for the development of companion diagnostics.
March 2017—Streck’s CE-marked antibiotic resistance monitoring and detection (ARM-D) kits are now available. The Streck ARM-D kits, AmpC and β-lactamase, are multiplex real-time PCR reagents for the detection of more than 450 β-lactamase gene targets.
March 2017—LGC Maine Standards added rheumatoid factor to its Validate SP2 calibration verification/linearity test kit. Validate SP2 evaluates albumin, C-reactive protein, haptoglobin, prealbumin, and rheumatoid factor in a human serum base. Each kit is prepared using the CLSI-recommended “equal delta” method for linearity testing and is liquid, ready to use.
March 2017—Qiagen announced it submitted its QuantiFeron-TB Gold Plus, the fourth generation of the modern blood test for detecting tuberculosis infection, for premarket approval by the Food and Drug Administration.
March 2017—Ortho Clinical Diagnostics has submitted a premarket approval application to the U.S. Food and Drug Administration for the Vitros Immunodiagnostic Products HIV Combo Assay for use on the Vitros 3600 immunodiagnostic system.
March 2017—Streck’s Para 12 Extend, a hematology control with three distinct populations of lymphocytes, mononuclears, and granulocytes, is now assayed for the Mindray BC-3600. Varying percentages are also offered in the low abnormal, normal, and high abnormal levels to test the accuracy and precision of the reported white cell populations.
March 2017—LGC Maine Standards’ Validate D-Dimer calibration verification/linearity test kit received FDA 510(k) clearance for use on Stago STA-R Evolution analyzers.
